University Of California, San Francisco

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors

Phase 2

Completed

Conditions: Paraganglioma
Pheochromocytoma

Interventions: Radiation: 131I-MIBG

First Posted Date: 2011-08-10

Last Posted Date: 2018-09-18

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 50

Registration Number: NCT01413503

Locations: 🇺🇸
UCSF, San Francisco, California, United States

The Effects of Sedentarism on Vascular Function, Inflammation, and Insulin Resistance

Phase 2

Terminated

Conditions: Peripheral Arterial Disease
Insulin Resistance
Metabolic Syndrome
Endothelial Dysfunction

Interventions: Dietary Supplement: Fish Oil (Omega-3 Fatty Acids)

First Posted Date: 2011-08-09

Last Posted Date: 2013-11-07

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 5

Registration Number: NCT01412216

Locations: 🇺🇸
University of California San Francisco, San Francisco, California, United States

Drug-Drug Interaction Study With Metformin and Nizatidine

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Metformin
Drug: Metformin and nizatidine

First Posted Date: 2011-08-04

Last Posted Date: 2014-04-10

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 10

Registration Number: NCT01409395

Locations: 🇺🇸
Ucsf Ctsi Crc, San Francisco, California, United States

Treatment for the Mental Health Impact of Killing in War

Completed

Conditions: Posttraumatic Stress Disorder (PTSD)

First Posted Date: 2011-08-01

Last Posted Date: 2014-08-18

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 8

Registration Number: NCT01406834

Locations: 🇺🇸
San Francisco VA Medical Center, San Francisco, California, United States

Drug-drug Interaction Study With Metformin and Imatinib

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Imatinib
Drug: Metformin

First Posted Date: 2011-07-28

Last Posted Date: 2014-04-10

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 11

Registration Number: NCT01404715

Locations: 🇺🇸
Ucsf Ctsi Crc, San Francisco, California, United States

Project RAP: Family-based HIV Prevention in the Juvenile Drug Court

Not Applicable

Completed

Conditions: HIV/AIDS

Interventions: Other: Adolescent Only Health Promotion
Behavioral: Family-Based HIV prevention

First Posted Date: 2011-07-27

Last Posted Date: 2020-05-12

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 120

Registration Number: NCT01403298

Locations: 🇺🇸
Rhode Island Hospital, Providence, Rhode Island, United States

Effects of Gastric pH on the Pharmacokinetics of Dasatinib

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Dasatinib plus Rabeprazole
Drug: Dasatinib plus Rabeprazole AND Betaine Hydrochloride
Drug: Dasatinib

First Posted Date: 2011-07-20

Last Posted Date: 2015-04-28

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 10

Registration Number: NCT01398046

Locations: 🇺🇸
Clinical Research Center, UCSF, San Francisco, California, United States

Effects of Sleep Duration and Architecture on Insulin Sensitivity

Not Applicable

Completed

Conditions: Insulin Resistance

Interventions: Behavioral: Sleep restriction

First Posted Date: 2011-07-19

Last Posted Date: 2021-07-19

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 10

Registration Number: NCT01396941

Locations: 🇺🇸
UCSF San Francisco General Hospital, San Francisco, California, United States

Environmental and Genetic Risk Factors for Pediatric Multiple Sclerosis

Completed

Conditions: Pediatric Multiple Sclerosis

First Posted Date: 2011-07-18

Last Posted Date: 2018-10-18

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 1276

Registration Number: NCT01396343

Locations: 🇺🇸
The Blue Bird Circle Clinic for MS at Texas Children's Hospital, Houston, Texas, United States
🇺🇸
Pediatric Neurology Clinic, Primary Children's Hospital, Salt Lake City, Utah, United States
🇺🇸
Pediatric MS Clinic, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States

and more 14 locations

Developing Individualized Strategies to Prevent Nausea and Vomiting

Not Applicable

Withdrawn

Conditions: Postoperative Nausea and Vomiting
Genetic Polymorphisms

Interventions: Drug: Ondansetron
Drug: Lorazepam
Drug: Aprepitant

First Posted Date: 2011-07-13

Last Posted Date: 2013-11-14

Lead Sponsor: University of California, San Francisco

Registration Number: NCT01393288

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸
Brigham & Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States

and more 3 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy